Clinical experience with exenatide in a routine secondary care diabetes clinic.

Abstract:

:Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA(1c) were 114.9+/-20.6 kg, 10.3+/-2.1% at initiation; 108.0+/-15.3 kg (p<0.0001), 9.0+/-2.1% (p<0.001) at 3 months; 109.2+/-18.2 kg (p<0.0001), 9.5+/-2.3% (p=0.08) at 6 months. Exenatide appears effective in reducing HBA(1c) and weight.

journal_name

Prim Care Diabetes

journal_title

Primary care diabetes

authors

Natarajan B,Edavalath M,Davies J,Jenkins L,Marshall-Richards N,Evans D,Price DE,Bain SC,Stephens JW

doi

10.1016/j.pcd.2009.11.001

subject

Has Abstract

pub_date

2010-04-01 00:00:00

pages

57-60

issue

1

eissn

1751-9918

issn

1878-0210

pii

S1751-9918(09)00146-6

journal_volume

4

pub_type

杂志文章